June 10, 2021 08:00 AM EDTUpdated 10:45 AM
Financing

Syn­thekine nabs megaround in bid to edge out Mer­ck, Sanofi in IL-2 sprint

Jason Mast

Editor

Nine months af­ter launch­ing out of Stan­ford with $82 mil­lion and a port­fo­lio of en­gi­neered cy­tokines, Syn­thekine has land­ed a $107.5 mil­lion Se­ries B …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times